Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risedronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 12/20 | 0.97 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.97 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risedronic Acid SCHEMBL18378 | 0.98 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL29362587 | 0.98 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4989214 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2115050 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3771017 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3170751 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL22720092 | 0.95 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL22720090 | 0.95 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4643040 | 0.90 | FDPS (0.83) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL10001488 | 0.89 | FDPS (0.82) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110063939-B | Hollow hydroxyapatite drug-loaded particle for shock wave mediated release and preparation method thereof | 邢更彦 | 2021-08-17 | — | — | CN | claimed |
| CN-112891621-A | Artificial bone material carrying anti-osteoporosis medicine and method for preparing artificial bone | 中南大学湘雅医院 | 2021-06-04 | — | — | CN | claimed |
| CN-112724172-A | Risedronate calcium complex and preparation method thereof | 华南理工大学 | 2021-04-30 | — | — | CN | claimed |
| EP-1252170-B2 | SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID SODIUM AS THE HEMIPENTAHYDRATE OR MONOHYDRATE | WARNER CHILCOTT CO LLC (PR) | 2013-11-06 | — | — | EP | claimed |
| EP-1981896-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RISEDRONATE SODIUM HEMI-PENTAHYDRATE | AUROBINDO PHARMA LTD (IN) | 2013-03-13 | — | — | EP | claimed |
| CN-101601661-A | A kind of risedronic acid sodium tablet and preparation method thereof | KUNMING JIDA PHARMACEUTICAL CO (CN) | 2009-12-16 | — | — | CN | claimed |
| US-20090182147-A1 | PROCESS FOR THE PREPARATION OF PURE RISEDRONIC ACID OR SALTS | M/S. IND SWIFT LABORATORIES LIMITED (IN) | 2009-07-16 | — | — | US | claimed |
| US-7485726-B2 | Process for the preparation of risedronate sodium hemi-pentahydrate | AUROBINDO PHARMA LTD. (IN) | 2009-02-03 | — | — | US | claimed |
| EP-2016084-A2 | PROCESS FOR THE PREPARATION OF PURE RISEDRONIC ACID OR SALTS | Ind-Swift Laboratories Limited (IN) | 2009-01-21 | — | — | EP | claimed |
| US-20080300408-A1 | Process for Preparing a Pure Polymorphic Form of 3-Pyridyl-1-Hydroxyethylidine-1, 1-Bisphosphonic Acid Sodium Salt | JUBILANT ORGANOSYS LIMITED (IN) | 2008-12-04 | — | — | US | claimed |
| WO-2007132478-A2 | PROCESS FOR THE PREPARATION OF PURE RISEDRONIC ACID OR SALTS | IND-SWIFT LABORATORIES LIMITED (IN) | 2007-11-22 | — | — | WO | claimed |
| EP-1828214-A1 | PROCESS FOR PREPARING A PURE POLYMORPHIC FORM OF 3-PYRIDYL-1-HYDROXYETHYLIDINE-1,1-BISPHOSPHONIC ACID SODIUM SALT | Jubilant Organosys Limited (IN) | 2007-09-05 | — | — | EP | claimed |
| CN-101024654-A | Novel polymorphs and pseudopolymorphs of risedronate sodium | TEVA PHARMACEUTICAL INDUDSTRIE (IL) | 2007-08-29 | — | — | CN | claimed |
| US-20070173484-A1 | Process for the preparation of risedronate sodium hemi-pentahydrate | AUROBINDO PHARMA LTD. (IN) | 2007-07-26 | — | — | US | claimed |
| WO-2006051553-A1 | PROCESS FOR PREPARING A PURE POLYMORPHIC FORM OF 3-PYRIDYL-1-HYDROXYETHYLIDINE-1,1-BISPHOSPHONIC ACID SODIUM SALT | JUBILANT ORGANOSYS LIMITED (IN) | 2006-05-18 | — | — | WO | claimed |
| US-20050260272-A1 | Method of forming microparticles that include a bisphosphonate and a polymer | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 2005-11-24 | — | — | US | claimed |
| CN-1658842-A | Novel polymorphs and pseudopolymorphs of risedronate sodium | TEVA PHARMACEUTICAL INDUDSTRIE (IL) | 2005-08-24 | — | — | CN | claimed |
| EP-1252170-B1 | SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID SODIUM AS THE HEMIPENTAHYDRATE OR MONOHYDRATE | PROCTER & GAMBLE (US) | 2004-08-18 | — | — | EP | claimed |
| US-6410520-B2 | HEATING IN AQUEOUS SOLUTION | THE PROCTER & GAMBLE COMPANY | 2002-06-25 | — | — | US | claimed |
| US-20020002282-A1 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2002-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173484-A1 | Process for the preparation of risedronate sodium hemi-pentahydrate | PTH1R, PHPT1, HPD | FDPS 61/4885BTN3A1 1592/4885PDE3A 1955/4885 |
| US-20020002282-A1 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate | PHPT1, PPA1, BPGM | FDPS 136/4885BTN3A1 792/4885PDE3A 2848/4885 |
| US-20090182147-A1 | PROCESS FOR THE PREPARATION OF PURE RISEDRONIC ACID OR SALTS | BPGM, PTH1R, PPIP5K2 | FDPS 17/4885BTN3A1 2785/4885PDE3A 2745/4885 |
| US-20080300408-A1 | Process for Preparing a Pure Polymorphic Form of 3-Pyridyl-1-Hydroxyethylidine-1, 1-Bisphosphonic Acid Sodium Salt | BPGM, ENPP1, SLC20A1 | FDPS 458/4885BTN3A1 2406/4885PDE3A 2576/4885 |
| US-20050260272-A1 | Method of forming microparticles that include a bisphosphonate and a polymer | PHOSPHO1, PTH1R, SOST | FDPS 300/4885BTN3A1 2912/4885PDE3A 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.